Please assess the completion status of the following clinical trial:

Trial Title: ALK27-001: A Study of Trospium Inhalation Powder (TrIP)Administered to Subjects With COPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female COPD subjects between the ages of 40 and 80 years~* Body mass index between 18 and 35~* Medically healthy (other than COPD)~* FEV1/FVC less than or equal to 0.70~* Current non-smoker or able to abstain from smoking for at least 8 hours postdose~* Within the previous 6 months, demonstrated improvement in FEV1 (greater than or equal to 10%) 1 hour following administration of ipratropium bromide inhalation (4 puffs)~* Females of childbearing potential must agree to use an acceptable method of contraception for the duration of the study~Exclusion Criteria:~* Asthma in the last 10 years~* Allergic rhinitis, atopy, cystic fibrosis, bronchiectasis, or tuberculosis~* Bladder neck obstruction, including urinary retention or known symptomatic prostatic hypertrophy not controlled with medication~* Narrow angle glaucoma~* Tachyarrhythmia~* Alcohol dependence or illicit drug abuse within the past year~* Using long-term oxygen therapy~* Female subjects who are pregnant or breastfeeding~* Participating in another clinical trial

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Represents Dose A in the Dosing Sequence assignments.
- TrIP-2D (100mcg) (Type: EXPERIMENTAL): Represents Dose B
- TrIP-2SS (100mcg) (Type: EXPERIMENTAL): Represents Dose C
- TrIP-2D (400mcg) (Type: EXPERIMENTAL): Represents Dose D
- TrIP-2SS (100mcg) + Foradil (12mcg) (Type: EXPERIMENTAL): Represents Dose E. All subjects received Dose E as their final (5th) dose, after completing their initial 4 single doses according to their sequence assignment.

Based on this trial design, predict the completion outcome and termination type (if applicable).